US health panel recommends easing restrictions on controversial peptides

A federal health advisory panel narrowly recommended easing restrictions on several injectable peptides, including BPC-157, TB-500, and KPV, which are popular among wellness influencers and celebrities. The panel, whose members include individuals linked to the peptide industry, voted 8-6 to suggest the FDA remove current restrictions barring pharmacies from compounding these substances. This recommendation comes despite warnings from FDA scientists about the lack of evidence for the peptides' safety and effectiveness. The panel's vote is advisory, but it is expected to support Health Secretary Robert F. Kennedy Jr., who has expressed support for peptides. If the FDA accepts the advice, telehealth companies may increase marketing of these peptides for unproven wellness and cosmetic uses.

The US Food and Drug Administration's Pharmacy Compounding Advisory Committee will meet to decide if seven controversial peptides can be dispensed by licensed pharmacies with prescriptions. These compounds, promoted for various wellness uses like sleep, muscle growth, and anti-aging, have surged in popularity, driven by social media and endorsements from figures like Robert F. Kennedy Jr. The FDA has expressed concerns about the evidence supporting their safety and efficacy. The review will determine if peptides such as BPC-157 and TB-500, marketed for conditions ranging from ulcerative colitis to obesity and insomnia, can move from an unregulated market to regulated access.